Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Firsekibart in Mild to Moderate Systemic Lupus Erythematosus
NCT07381465Phase 4Active, not recruiting
- Sponsor
- Chinese SLE Treatment And Research Group
- Start
- Jun 2026
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of genakumab in systemic lupus erythematosus (SLE), sponsored by Chinese SLE Treatment And Research Group. Started Jun 2026; status: active, not recruiting.
02
Drugs
genakumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT07381465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07381465.